Chemotherapy in Canine Acute Megakaryoblastic Leukemia: A Case Report and Review of the Literature
Acute myeloid leukemia (AML) in dogs is a rare disease with poor prognosis. In most subjects, palliative treatment or euthanasia is performed. A 3.5-year-old male castrated labrador with AML-M7, which was treated with induction polychemotherapy (8 cycles) using vincristine (0.5 mg/m 2 /cycle), dauno...
Gespeichert in:
| Veröffentlicht in: | In vivo (Athens) 2009-11, Vol.23 (6), p.911-918 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 918 |
|---|---|
| container_issue | 6 |
| container_start_page | 911 |
| container_title | In vivo (Athens) |
| container_volume | 23 |
| creator | Willmann, Michael Müllauer, Leonhard Schwendenwein, Ilse Wolfesberger, Birgitt Kleiter, Miriam Pagitz, Maximilian Hadzijusufovic, Emir Shibly, Sarina Reifinger, Martin Thalhammer, Johann G Valent, Peter |
| description | Acute myeloid leukemia (AML) in dogs is a rare disease with poor prognosis. In most subjects, palliative treatment or euthanasia
is performed. A 3.5-year-old male castrated labrador with AML-M7, which was treated with induction polychemotherapy (8 cycles)
using vincristine (0.5 mg/m 2 /cycle), daunorubicin (20 mg/m 2 /cycle), cytosine arabinoside (ARA-C, 100 mg/m 2 /cycle) and prednisolone (1 mg/kg/day) is reported. Treatment was well tolerated and complete remission was achieved. Postinduction
chemotherapy consisted of ARA-C, daunorubicin and prednisolone. After 3, 5 and 18 months, the subject relapsed. Each relapse
was treated with ARA-C (up to 1,000 mg/m 2 ) and etoposide or daunorubicin. Again, no severe side-effects occurred and the disease was controlled, with 37 chemotherapy-cycles
(ARA-C, 3 x 1,000 mg/m 2 /cycle), for 24 months. Based on a literature-search, this is the first report documenting a long-term response of canine
AML, probably resulting from the high-dose ARA-C. Clinical trials using high-dose ARA-C are now required to confirm antileukemic
efficacy in canine leukemias. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_733695172</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733695172</sourcerecordid><originalsourceid>FETCH-LOGICAL-h239t-93cd2f4ad0b0eeef7362e0db7fb616d9a9eaa62765a741a811007e65bc38adaa3</originalsourceid><addsrcrecordid>eNo10E1Lw0AQBuBFFFurf0H2IHgK7Eezm3grwS-oCKLgbZkkk2ZtvsxuWvrvXWhlDu8cHl6YOSNzrlMe6XiZnpM5E3ESJTH_npEr534YU5oxcUlmIoQMMyd5VmPb-xpHGA7UdjSDznZIV8Xkkb7hBrYwHvq8AedtQdc4bbG18EBXQTqkHzj0o6fQlWHdWdzTvqKhjq6tD51-GvGaXFTQOLw55YJ8PT1-Zi_R-v35NVuto1rI1EepLEpRLaFkOUPESkslkJW5rnLFVZlCigBKaBWDXnJIOGdMo4rzQiZQAsgFuT_2DmP_O6HzprWuwKaBDvvJGS2lSmOuRZC3JznlLZZmGG0brjT_bwng7ghqu6n3dkTjWmiawKWxOyGNMinn8g9K8mye</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733695172</pqid></control><display><type>article</type><title>Chemotherapy in Canine Acute Megakaryoblastic Leukemia: A Case Report and Review of the Literature</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Willmann, Michael ; Müllauer, Leonhard ; Schwendenwein, Ilse ; Wolfesberger, Birgitt ; Kleiter, Miriam ; Pagitz, Maximilian ; Hadzijusufovic, Emir ; Shibly, Sarina ; Reifinger, Martin ; Thalhammer, Johann G ; Valent, Peter</creator><creatorcontrib>Willmann, Michael ; Müllauer, Leonhard ; Schwendenwein, Ilse ; Wolfesberger, Birgitt ; Kleiter, Miriam ; Pagitz, Maximilian ; Hadzijusufovic, Emir ; Shibly, Sarina ; Reifinger, Martin ; Thalhammer, Johann G ; Valent, Peter</creatorcontrib><description>Acute myeloid leukemia (AML) in dogs is a rare disease with poor prognosis. In most subjects, palliative treatment or euthanasia
is performed. A 3.5-year-old male castrated labrador with AML-M7, which was treated with induction polychemotherapy (8 cycles)
using vincristine (0.5 mg/m 2 /cycle), daunorubicin (20 mg/m 2 /cycle), cytosine arabinoside (ARA-C, 100 mg/m 2 /cycle) and prednisolone (1 mg/kg/day) is reported. Treatment was well tolerated and complete remission was achieved. Postinduction
chemotherapy consisted of ARA-C, daunorubicin and prednisolone. After 3, 5 and 18 months, the subject relapsed. Each relapse
was treated with ARA-C (up to 1,000 mg/m 2 ) and etoposide or daunorubicin. Again, no severe side-effects occurred and the disease was controlled, with 37 chemotherapy-cycles
(ARA-C, 3 x 1,000 mg/m 2 /cycle), for 24 months. Based on a literature-search, this is the first report documenting a long-term response of canine
AML, probably resulting from the high-dose ARA-C. Clinical trials using high-dose ARA-C are now required to confirm antileukemic
efficacy in canine leukemias.</description><identifier>ISSN: 0258-851X</identifier><identifier>EISSN: 1791-7549</identifier><identifier>PMID: 20023232</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>Animals ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bone Marrow Cells - drug effects ; Bone Marrow Cells - pathology ; Cytarabine - administration & dosage ; Daunorubicin - administration & dosage ; Dog Diseases - drug therapy ; Dogs ; Etoposide - administration & dosage ; Leukemia, Megakaryoblastic, Acute - drug therapy ; Leukemia, Megakaryoblastic, Acute - pathology ; Leukemia, Megakaryoblastic, Acute - veterinary ; Male ; Prednisolone - administration & dosage ; Remission Induction ; Secondary Prevention ; Vincristine - administration & dosage</subject><ispartof>In vivo (Athens), 2009-11, Vol.23 (6), p.911-918</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20023232$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Willmann, Michael</creatorcontrib><creatorcontrib>Müllauer, Leonhard</creatorcontrib><creatorcontrib>Schwendenwein, Ilse</creatorcontrib><creatorcontrib>Wolfesberger, Birgitt</creatorcontrib><creatorcontrib>Kleiter, Miriam</creatorcontrib><creatorcontrib>Pagitz, Maximilian</creatorcontrib><creatorcontrib>Hadzijusufovic, Emir</creatorcontrib><creatorcontrib>Shibly, Sarina</creatorcontrib><creatorcontrib>Reifinger, Martin</creatorcontrib><creatorcontrib>Thalhammer, Johann G</creatorcontrib><creatorcontrib>Valent, Peter</creatorcontrib><title>Chemotherapy in Canine Acute Megakaryoblastic Leukemia: A Case Report and Review of the Literature</title><title>In vivo (Athens)</title><addtitle>In Vivo</addtitle><description>Acute myeloid leukemia (AML) in dogs is a rare disease with poor prognosis. In most subjects, palliative treatment or euthanasia
is performed. A 3.5-year-old male castrated labrador with AML-M7, which was treated with induction polychemotherapy (8 cycles)
using vincristine (0.5 mg/m 2 /cycle), daunorubicin (20 mg/m 2 /cycle), cytosine arabinoside (ARA-C, 100 mg/m 2 /cycle) and prednisolone (1 mg/kg/day) is reported. Treatment was well tolerated and complete remission was achieved. Postinduction
chemotherapy consisted of ARA-C, daunorubicin and prednisolone. After 3, 5 and 18 months, the subject relapsed. Each relapse
was treated with ARA-C (up to 1,000 mg/m 2 ) and etoposide or daunorubicin. Again, no severe side-effects occurred and the disease was controlled, with 37 chemotherapy-cycles
(ARA-C, 3 x 1,000 mg/m 2 /cycle), for 24 months. Based on a literature-search, this is the first report documenting a long-term response of canine
AML, probably resulting from the high-dose ARA-C. Clinical trials using high-dose ARA-C are now required to confirm antileukemic
efficacy in canine leukemias.</description><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bone Marrow Cells - drug effects</subject><subject>Bone Marrow Cells - pathology</subject><subject>Cytarabine - administration & dosage</subject><subject>Daunorubicin - administration & dosage</subject><subject>Dog Diseases - drug therapy</subject><subject>Dogs</subject><subject>Etoposide - administration & dosage</subject><subject>Leukemia, Megakaryoblastic, Acute - drug therapy</subject><subject>Leukemia, Megakaryoblastic, Acute - pathology</subject><subject>Leukemia, Megakaryoblastic, Acute - veterinary</subject><subject>Male</subject><subject>Prednisolone - administration & dosage</subject><subject>Remission Induction</subject><subject>Secondary Prevention</subject><subject>Vincristine - administration & dosage</subject><issn>0258-851X</issn><issn>1791-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo10E1Lw0AQBuBFFFurf0H2IHgK7Eezm3grwS-oCKLgbZkkk2ZtvsxuWvrvXWhlDu8cHl6YOSNzrlMe6XiZnpM5E3ESJTH_npEr534YU5oxcUlmIoQMMyd5VmPb-xpHGA7UdjSDznZIV8Xkkb7hBrYwHvq8AedtQdc4bbG18EBXQTqkHzj0o6fQlWHdWdzTvqKhjq6tD51-GvGaXFTQOLw55YJ8PT1-Zi_R-v35NVuto1rI1EepLEpRLaFkOUPESkslkJW5rnLFVZlCigBKaBWDXnJIOGdMo4rzQiZQAsgFuT_2DmP_O6HzprWuwKaBDvvJGS2lSmOuRZC3JznlLZZmGG0brjT_bwng7ghqu6n3dkTjWmiawKWxOyGNMinn8g9K8mye</recordid><startdate>20091101</startdate><enddate>20091101</enddate><creator>Willmann, Michael</creator><creator>Müllauer, Leonhard</creator><creator>Schwendenwein, Ilse</creator><creator>Wolfesberger, Birgitt</creator><creator>Kleiter, Miriam</creator><creator>Pagitz, Maximilian</creator><creator>Hadzijusufovic, Emir</creator><creator>Shibly, Sarina</creator><creator>Reifinger, Martin</creator><creator>Thalhammer, Johann G</creator><creator>Valent, Peter</creator><general>International Institute of Anticancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20091101</creationdate><title>Chemotherapy in Canine Acute Megakaryoblastic Leukemia: A Case Report and Review of the Literature</title><author>Willmann, Michael ; Müllauer, Leonhard ; Schwendenwein, Ilse ; Wolfesberger, Birgitt ; Kleiter, Miriam ; Pagitz, Maximilian ; Hadzijusufovic, Emir ; Shibly, Sarina ; Reifinger, Martin ; Thalhammer, Johann G ; Valent, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h239t-93cd2f4ad0b0eeef7362e0db7fb616d9a9eaa62765a741a811007e65bc38adaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bone Marrow Cells - drug effects</topic><topic>Bone Marrow Cells - pathology</topic><topic>Cytarabine - administration & dosage</topic><topic>Daunorubicin - administration & dosage</topic><topic>Dog Diseases - drug therapy</topic><topic>Dogs</topic><topic>Etoposide - administration & dosage</topic><topic>Leukemia, Megakaryoblastic, Acute - drug therapy</topic><topic>Leukemia, Megakaryoblastic, Acute - pathology</topic><topic>Leukemia, Megakaryoblastic, Acute - veterinary</topic><topic>Male</topic><topic>Prednisolone - administration & dosage</topic><topic>Remission Induction</topic><topic>Secondary Prevention</topic><topic>Vincristine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Willmann, Michael</creatorcontrib><creatorcontrib>Müllauer, Leonhard</creatorcontrib><creatorcontrib>Schwendenwein, Ilse</creatorcontrib><creatorcontrib>Wolfesberger, Birgitt</creatorcontrib><creatorcontrib>Kleiter, Miriam</creatorcontrib><creatorcontrib>Pagitz, Maximilian</creatorcontrib><creatorcontrib>Hadzijusufovic, Emir</creatorcontrib><creatorcontrib>Shibly, Sarina</creatorcontrib><creatorcontrib>Reifinger, Martin</creatorcontrib><creatorcontrib>Thalhammer, Johann G</creatorcontrib><creatorcontrib>Valent, Peter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>In vivo (Athens)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Willmann, Michael</au><au>Müllauer, Leonhard</au><au>Schwendenwein, Ilse</au><au>Wolfesberger, Birgitt</au><au>Kleiter, Miriam</au><au>Pagitz, Maximilian</au><au>Hadzijusufovic, Emir</au><au>Shibly, Sarina</au><au>Reifinger, Martin</au><au>Thalhammer, Johann G</au><au>Valent, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemotherapy in Canine Acute Megakaryoblastic Leukemia: A Case Report and Review of the Literature</atitle><jtitle>In vivo (Athens)</jtitle><addtitle>In Vivo</addtitle><date>2009-11-01</date><risdate>2009</risdate><volume>23</volume><issue>6</issue><spage>911</spage><epage>918</epage><pages>911-918</pages><issn>0258-851X</issn><eissn>1791-7549</eissn><abstract>Acute myeloid leukemia (AML) in dogs is a rare disease with poor prognosis. In most subjects, palliative treatment or euthanasia
is performed. A 3.5-year-old male castrated labrador with AML-M7, which was treated with induction polychemotherapy (8 cycles)
using vincristine (0.5 mg/m 2 /cycle), daunorubicin (20 mg/m 2 /cycle), cytosine arabinoside (ARA-C, 100 mg/m 2 /cycle) and prednisolone (1 mg/kg/day) is reported. Treatment was well tolerated and complete remission was achieved. Postinduction
chemotherapy consisted of ARA-C, daunorubicin and prednisolone. After 3, 5 and 18 months, the subject relapsed. Each relapse
was treated with ARA-C (up to 1,000 mg/m 2 ) and etoposide or daunorubicin. Again, no severe side-effects occurred and the disease was controlled, with 37 chemotherapy-cycles
(ARA-C, 3 x 1,000 mg/m 2 /cycle), for 24 months. Based on a literature-search, this is the first report documenting a long-term response of canine
AML, probably resulting from the high-dose ARA-C. Clinical trials using high-dose ARA-C are now required to confirm antileukemic
efficacy in canine leukemias.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>20023232</pmid><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0258-851X |
| ispartof | In vivo (Athens), 2009-11, Vol.23 (6), p.911-918 |
| issn | 0258-851X 1791-7549 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733695172 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Animals Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone Marrow Cells - drug effects Bone Marrow Cells - pathology Cytarabine - administration & dosage Daunorubicin - administration & dosage Dog Diseases - drug therapy Dogs Etoposide - administration & dosage Leukemia, Megakaryoblastic, Acute - drug therapy Leukemia, Megakaryoblastic, Acute - pathology Leukemia, Megakaryoblastic, Acute - veterinary Male Prednisolone - administration & dosage Remission Induction Secondary Prevention Vincristine - administration & dosage |
| title | Chemotherapy in Canine Acute Megakaryoblastic Leukemia: A Case Report and Review of the Literature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T21%3A27%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemotherapy%20in%20Canine%20Acute%20Megakaryoblastic%20Leukemia:%20A%20Case%20Report%20and%20Review%20of%20the%20Literature&rft.jtitle=In%20vivo%20(Athens)&rft.au=Willmann,%20Michael&rft.date=2009-11-01&rft.volume=23&rft.issue=6&rft.spage=911&rft.epage=918&rft.pages=911-918&rft.issn=0258-851X&rft.eissn=1791-7549&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E733695172%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733695172&rft_id=info:pmid/20023232&rfr_iscdi=true |